

Exhibit 1

Evidence-Based Education and Advertising Fund Expenditures by program
Fiscal Years 2022, 2023 and FY 2024 est.

	FY 2022	FY 2023	Estimated FY 2024
Prescription Drug Education	\$356,509	\$457,406	\$500,000
Opioid Antagonist Program	\$1,830,717	\$1,851,865	\$1,900,000
Prescription Drug Monitoring Program	\$506,143	\$521,124	\$525,000
Antibiotic Stewardship	\$6,741	\$20,208	\$25,000
Prescription Drug Disposal	\$558,111	\$557,772	\$600,000
Substance Misuse Prevention Council	\$236,751	\$218,213	\$220,000
Total	\$3,494,972	\$3,626,588	\$3,770,000

FY 2025 Gov. Rec.	\$3,544,820
H.883 (House Rec. Bill Bill)	<u>\$1,980,000</u>
	\$5,524,820

Exhibit 2

Evidence-Based Education and Advertising Fund Balance,
Fiscal Years 2022, 2023 and FY 2024 est. (x million)

Fiscal Year	Prior Year Ending fund Balance	Revenues	Expenses	Ending Fund Balance
2022	\$2.3	\$3.8	(\$3.5)	\$2.6
2023	\$2.6	\$5.3	(\$3.6)	\$4.3
2024 Est.	\$4.3	\$4.7	(\$3.8)	\$5.2

JFO Draft/ntl
03 27 24